Australia has launched a 20,000-person genomics study to uncover new genetic variants related to depression. It's part of a wider 200,000-person international initiative, the largest-ever undertaking in the field.
Why do some people respond to antidepressant medications, while others gain no symptom relief at all?
That's just one of many million-dollar questions that confound drug developers and healthcare providers working in the field of mental health. The unknowns complicate clinical trials, treatment decisions, and of course, greatly impact patients.
